BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24

• 

  Weight loss

  Novo Nordisk starts trialing lower maintenance doses of oral Wegovy

  The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.

  August 21, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• Press Releases

  PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner

  August 21, 2026

   · 

  8 min read
• Press Releases

  Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

  August 21, 2026

   · 

  5 min read
• Press Releases

  Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

  August 21, 2026

   · 

  1 min read
• Press Releases

  Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

  August 21, 2026

   · 

  12 min read
• Press Releases

  Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement

  August 21, 2026

   · 

  19 min read
• Press Releases

  Belite Bio Announces Oral Presentations at Two Upcoming August 2026 Medical Conferences

  August 21, 2026

   · 

  4 min read
• Press Releases

  AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

  August 21, 2026

   · 

  12 min read
• Press Releases

  CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist

  August 21, 2026

   · 

  3 min read
• Press Releases

  Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

  August 21, 2026

   · 

  10 min read